Biodexa acquires rights to potential diabetes treatment
- Biodexa Pharmaceuticals shares double after licensing deal for tolimidone
- Stock hits 52-week low of $2.26
- Biodexa acquires rights to tolimidone from Adhera Therapeutics
- Biodexa to develop, manufacture, and commercialize the drug
- Plans to conduct Phase 1b dose confirmation study for Type 1 diabetes
- Tolimidone originally discovered by Pfizer, developed for gastric ulcers
- Melior and Bukwang Pharmaceutical evaluated drug for Type 2 diabetes
Biodexa Pharmaceuticals shares have doubled to $5.90 following the company’s agreement to acquire Adhera Therapeutics’s rights to tolimidone, a potential diabetes treatment. The stock had previously hit a 52-week low of $2.26 and has seen a decline of almost 99% in the past year. Biodexa will now have an exclusive license from Melior Pharmaceuticals to develop, manufacture, and commercialize the drug. The company plans to conduct a Phase 1b dose confirmation study in collaboration with the Alberta Diabetes Institute to determine the minimum effective dose for treating Type 1 diabetes. Tolimidone, originally discovered by Pfizer for gastric ulcers, showed promising results in Phase 2 studies for Type 2 diabetes when evaluated by Melior and Bukwang Pharmaceutical.
Public Companies: Biodexa Pharmaceuticals (N/A), Adhera Therapeutics (N/A), Melior Pharmaceuticals (N/A), Pfizer (N/A), Bukwang Pharmaceutical (N/A)
Private Companies:
Key People:
Factuality Level: 7
Justification: The article provides information about Biodexa Pharmaceuticals acquiring the rights to tolimidone, a potential diabetes treatment. It mentions the stock price of Biodexa and its 52-week low, which are factual details. It also mentions the agreement with Melior Pharmaceuticals and the payment terms to Adhera and secured noteholders, which can be verified. The article also mentions Biodexa’s plans to develop tolimidone for Type 1 diabetes and the Phase 1b study with the Alberta Diabetes Institute, which are specific details about the company’s plans. The information about tolimidone being originally discovered by Pfizer and its development for gastric ulcers, as well as the Phase 2 studies for Type 2 diabetes, are also factual details. Overall, the article provides specific information about the acquisition and the plans for tolimidone, which can be fact-checked.
Noise Level: 7
Justification: The article provides relevant information about Biodexa Pharmaceuticals acquiring the rights to tolimidone, a potential diabetes treatment. It also mentions the stock’s performance and the company’s plans for developing the drug. However, there is some repetitive information and the article does not provide a thoughtful analysis of long-term trends or antifragility. It also lacks scientific rigor and intellectual honesty as it does not provide any evidence or data to support the claims made.
Financial Relevance: Yes
Financial Markets Impacted: Biodexa Pharmaceuticals
Presence of Extreme Event: No
Nature of Extreme Event: No
Impact Rating of the Extreme Event: No
Justification: The article pertains to financial topics as it discusses Biodexa Pharmaceuticals acquiring the rights to a potential diabetes treatment. However, there is no mention of any extreme event or its impact.
www.marketwatch.com 
